Evidence map›Paper›PMID 40683913›Full record

ArticleScientific reports2025

Uncovering the molecular signature of feline diffuse iris melanoma through transcriptomic analysis of disease severity.

D Kayes, B Blacklock, R McGeachan, E Scurrell, K Donnelly, L Murphy, A Fawkes, R Clark, A Meynert, H Becher and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

D KayesThe Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK. dkayes2@ed.ac.uk.
B BlacklockThe Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK.
R McGeachanThe Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK.
E ScurrellCytopath Veterinary Pathology, Ledbury, UK.
K DonnellyMRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
L MurphyEdinburgh Clinical Research Facility, The University of Edinburgh, Edinburgh, UK.
A FawkesEdinburgh Clinical Research Facility, The University of Edinburgh, Edinburgh, UK.
R ClarkEdinburgh Clinical Research Facility, The University of Edinburgh, Edinburgh, UK.
A MeynertInstitute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK.
H BecherThe Roslin Institute, The University of Edinburgh, Edinburgh, UK.
R PittawayDick White Referrals, Six Mile Bottom, UK.
G FrickerDick White Referrals, Six Mile Bottom, UK.
R Tetas PontRoyal Veterinary College, Queen Mother Hospital for Animals, Hatfield, UK.
A Suárez-BonnetRoyal Veterinary College, Queen Mother Hospital for Animals, Hatfield, UK.
K L Bowlt BlacklockThe Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh, UK. kelly.blacklock@ed.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Feline diffuse iris melanoma (FDIM) is the most common primary ocular tumour in cats, with metastatic disease occurring in 19-63% of patients. Greater intraocular invasion correlates with increased mortality. No effective therapeutics exist for metastatic FDIM, partly due to a lack of known molecular targets associated with aggressive tumour behaviour. Here, we define the transcriptomic landscape of FDIM in treatment-naïve cats using bulk RNA sequencing on laser capture microdissection and core biopsy specimens from formalin-fixed paraffin-embedded tissue. Samples included 'iris melanosis' (dysplastic melanocytes confined to the anterior iris; n = 7), 'early FDIM' (neoplastic melanocytes confined to the iris stroma; n = 13), and 'late FDIM' (neoplastic infiltration into the ciliary body and sclera; n = 13). Iris melanosis exhibited genetic overlap with early FDIM, supporting its reclassification as 'melanoma in situ'. Early FDIM showed upregulation of genes linked to tumour initiation, immune recruitment, and motility (e.g., STOX1, PEG3, XIAP, MCAM, VIM). Late FDIM exhibited immune microenvironment remodelling, immune evasion, and apoptosis inhibition (e.g., BIRC2, BIRC5, CCL2, HAVCR2), with downregulation of FOX1, FOXC2, and SOX11. These results provide critical biomarkers of disease severity, which may aid in the development of more accurate prognostic tests and more effective targeted therapies for FDIM.

Indexed as

Cat DiseasesIris NeoplasmsMelanomaTranscriptomeAnimalsCatsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticMaleSeverity of Illness IndexFeline diffuse iris melanomaGene expressionMelanoma metastasisTranscriptomeUveal melanoma

Identifiers

PMID40683913
PMCPMC12276267

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.